New study tracks MS drug safety in pregnancy
NCT ID NCT05688436
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This study follows about 1,178 pregnant women with multiple sclerosis to see if taking the drug diroximel fumarate (VUMERITY®) affects their babies. Researchers will compare birth outcomes among women who took the drug, those who took other MS drugs, and those who took no MS drugs during pregnancy. The main focus is on major birth defects, but they will also track miscarriages, stillbirths, and preterm births.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OptumInsight
RECRUITINGEden Prairie, Minnesota, 55344-2503, United States
Contact
Conditions
Explore the condition pages connected to this study.